RESEARCH TRIANGLE PARK, North Carolina--RIEMSER, a leader in oral surgery technology, has announced the launch of AlloSorb™.AlloSorb™ is a cost-competitive allograft that provides a natural structure and framework to build healthy bone in the regeneration process. The product is a STERILE-R allograft accredited by the American Association of Tissue Banks. AlloSorb™ uses a sterilization and processing method, Allowash®, a patented technology that helps minimize the risk of disease transmission by facilitating the removal of cellular elements from musculoskeletal tissue without degrading the tissues’ structural integrity. AlloSorb™ is low-dose irradiated. Furthermore, to achieve patient safety, the manufacturer’s screening process for donors meets or exceeds FDA regulations and AATB standards. AlloSorb™ is available in three types of particulate--mineralized cancellous, demineralized cortical, and mineralized cortical--in .5 cc, 1.0 cc, and 2.0 cc vials. It will soon be available in block form. “Our customers include oral surgeons, periodontists, and other implantologists who want RIEMSER to serve as a one-stop supplier for all their bone grafting needs, which is why we are pleased to add this safe, cost-competitive allograft product to our growing line,” says Vince Ellero, Director, National Sales. For more information, go to riemserdental.com/.To read more about RIEMSER, go to RIEMSER.To comment on this product, go to community.pennwelldentalgroup.com/.